Sign Up Today and Learn More About CytoReason Stock
Invest in or calculate the value of your shares in CytoReason or other pre-IPO companies through EquityZen's platform.
CytoReason Stock (CYTR)
CytoReason develops a cell-centered computational model of the human body designed to discover complex patterns in biological data.
About CytoReason Stock
Founded
2016
Industries
Science and Engineering, Health Care, Biotechnology
CytoReason Press Mentions
Stay in the know about the latest news on CytoReason
Digital Health 50: The most promising digital health startups of 2024
cbinsights • Dec 04, 2024
CytoReason Secures $80M from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific to Scale Its AI Disease Models and Establish US Hub in Cambridge, Massachusetts
finance • Aug 05, 2024
Nvidia, Pfizer lead $80 mln funding for Israeli medical AI tech firm CytoReason
reuters • Aug 05, 2024
Backed by Nvidia and Pfizer, Israeli AI medical startup raises $80m in fresh capital
timesofisrael • Aug 05, 2024
CytoReason raises $80 million, including from NVIDIA and Pfizer, to scale its AI disease models
calcalistech • Aug 02, 2024
CytoReason Management
Leadership team at CytoReason
Co-Founder
David Harel
Chief Scientist
Shai Shen-Orr
Join now and verify your accreditation status to gain access to:
- CytoReason current valuation
- CytoReason stock price
- Available deals in CytoReason and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in CytoReason stock?
Accredited investors can buy pre-IPO stock in companies like CytoReason through EquityZen funds. These investments are made available by existing CytoReason shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell CytoReason stock?
Shareholders can sell their CytoReason stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
